Health Care Related Organization – Page 3

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer’s Drug Pipeline

2 weeks ago talkbio0Tagged Acquisition, Agonist, Alzheimer 's disease, Microglia, Neurodegenerative Disorders, Phase 2 Trials, sanofi, TREM2, VG-3927, Vigil Neuroscience

Sanofi; Vigil Neuroscience; acquisition; Alzheimer’s disease; TREM2 agonist; VG-3927; microglia; neurodegenerative disease; Phase 2 trials; biotech deals

HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets

2 weeks ago talkbio0Tagged biosimilar competition, branded drugs, CHARGE Syndrome, Country, Drug Industry, drug price, executive order, Generic competition, most-favored, Organisation for Economic Co-Operation and Development

most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries

Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures

2 weeks ago talkbio0Tagged customs loophole, drug import duties, Drug Industry, first, minimis exemption, sale rule, tariff avoidance, trade compliance, Trump administration, U.S., US tariffs

first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo

2 weeks ago talkbio0Tagged Advisory Committees, enzalutamide, expansion, Inhibitor, Labels (device), Malignant neoplasm of prostate, mCRPC, PARP1 gene, Pfizer, talazoparib, Talzenna, unanimous vote, United States Food and Drug Administration

FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote

Moderna Shares Fall as Company Withdraws Flu/COVID-19 Combination Vaccine Application

2 weeks ago talkbio0Tagged Biologics License Application, Clinical Trials, COVID19 (disease), Effectiveness, Influenza, Moderna, mRNA-1083, Prices, United States Food and Drug Administration, Vaccines, Vaccines, Combined

Moderna; mRNA-1083; combination vaccine; flu; COVID-19; FDA; Biologics License Application; vaccine efficacy; clinical trial; share price

FDA Advisory Committee Splits Votes on Genentech and J&J Cancer Drugs

3 weeks ago talkbio0Tagged Advisory Committees, applicability, cancer drugs, Clinical Trials, Columvi, genentech, J&J, ODAC, STARGLO, United States Food and Drug Administration, Voting

FDA; advisory committee; Genentech; J&J; cancer drugs; Columvi; ODAC; clinical trials; diffuse large B-cell lymphoma; applicability; STARGLO; voting

‘Go ahead and do it’: Top RFK Jr. Deputy Dares Drugmakers Over Threats to Pull Manufacturing Amid Price Pressure

3 weeks ago talkbio0Tagged Big Pharma, Calley Means, CHARGE Syndrome, Drug Industry, drug price, executive order, HHS, Manufacturing, Prices, RFK Jr., Roche (company), threat

RFK Jr.; drug pricing; Calley Means; HHS; pharmaceutical industry; manufacturing threats; Roche; executive order; price limits; Big Pharma

Genentech Bets Again on Orionis With Potential $2B+ in Crowded Molecular Glue Space

3 weeks ago talkbio0Tagged Allo-Glue platform, Drug Discovery, genentech, Malignant Neoplasms, molecular glue, Neoplasms, Orionis Biosciences, Partnership, protein degraders

Genentech; Orionis Biosciences; molecular glue; oncology; drug discovery; cancer; partnership; biotech; protein degraders; Allo-Glue platform

Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707

3 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, China, Drug Development, Licensing Deal, Neoplasms, PD-1/VEGF bispecific antibody, Pfizer, SSGJ-707, upfront payment

Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development

SpyLock Technology: Recent News on Rapid Bispecific Antibody Screening

3 weeks ago talkbio0Tagged BiLockCatcher, Bio-Rad, bispecific antibody screening, Drug Development, high-throughput screening, Laboratory, Pioneer Antibody Discovery, Protein Engineering, SpyLock technology, SpyTag/SpyCatcher

SpyLock technology; bispecific antibody screening; Bio-Rad Laboratories; Pioneer Antibody Discovery Platform; high-throughput screening; protein engineering; SpyTag/SpyCatcher; BiLockCatcher; drug development